Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

9342-8530 Quebec Inc DGCRF

Healthcare Biotechnology
Diagnocure Inc is a Canada based biotechnology company. It is primarily engaged in the business activity of development and commercialization of products relating to the diagnosis of cancer. The group generates its revenue from research and license agreement. The head office of the company is located in Quebec, Canada.


GREY:DGCRF - Post by User

9342-8530 Quebec Inc
Bullboard Posts
User Avatar Image
(0)
•••
Comment by ready2go1on Jul 20, 2010 11:57am
375 Views
Post# 17281742

RE: News clinics offer the test

RE: News clinics offer the testMy hometown. I have never seen them discuss new tests that they are using which are not FDA approved yet. In general, companies from all over the world try to get them to trial their products, for free, just to get an endorsement.  They will use the tests/markers/equipment but will not allow their name to appear in any news release.
       I hate to say it, but Diagnocure will be acquired prior to the share price reaching our price point. We will get the run we are looking for, and some would say a home run but I expected so much more. and just like it was posted earlier, $1.00, give me a break.
     In my last post, I talked about what I have been discussing with a number of wealthy individuals. This article just fuels the fire and creates even more interest than I could have ever imagined. Phone has been ringing all morning.
We may have lost LeBron, but we gained PCA3.
     this is my last post
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities